VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
MCYMercury General Corporation
$107.47$6.0B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksMCYFinancials

Mercury General Corporation (MCY) Financials

30Y historyFree accessUpdated daily

The company has achieved a cyclical recovery in underwriting profitability, with the combined ratio improving to 84.7% in 2026Q1 as premium growth of 10.5% successfully offsets persistent claims severity.

MCY Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Revenue6.14B5.99B5.48B4.63B3.64B3.99B3.78B3.97B3.38B3.42B3.23B3.01B3.01B2.82B2.78B2.78B2.78B3.12B2.41B3.18B3.17B2.99B2.67B2.27B1.79B1.51B1.37B1.28B1.22B1.13B824.96M
Revenue Growth %9.7%9.44%18.27%27.08%-8.77%5.52%-4.73%17.53%-1.05%5.83%7.26%-0.08%6.76%1.35%0.22%0.05%-11.07%29.3%-24.05%0.32%5.91%12.13%17.77%26.83%18.53%10.32%6.66%4.79%8.35%36.73%20.67%
Medical Costs & Claims3.45B3.96B4.54B4.23B4.02B3.39B3.02B3.31B3.15B3B2.92B2.68B2.51B2.47B2.44B2.31B2.33B2.54B2.69B2.7B2.67B2.48B2.14B1.93B1.65B1.31B1.17B1.06B937.06M879.61M661.88M
Medical Cost Ratio %56.15%66.13%82.96%91.29%110.26%84.98%79.88%83.27%93.16%87.83%90.4%89.21%83.42%87.49%87.64%83.21%83.99%81.47%111.23%84.82%84.28%82.95%80.39%84.99%92.18%87.07%85.68%82.5%76.67%77.98%80.23%
Gross Profit2.69B2.03B932.86M403.25M-373.76M599.82M761.38M664.41M231.05M415.73M310M324.57M499.44M352.83M344.13M466.36M444.55M578.27M-271.07M482.44M498.15M510.06M523.35M340.15M139.64M194.87M195.58M224.17M285.06M248.33M163.09M
Gross Margin %43.85%33.87%17.04%8.71%-10.26%15.02%20.12%16.73%6.84%12.17%9.6%10.79%16.58%12.51%12.36%16.79%16.01%18.53%-11.23%15.18%15.72%17.05%19.61%15.01%7.82%12.93%14.32%17.5%23.33%22.02%19.77%
Gross Profit Growth %-117.55%131.33%207.89%-162.31%-21.22%14.6%187.56%-44.42%34.11%-4.49%-35.01%41.55%2.53%-26.21%4.9%-23.12%313.33%-156.19%-3.16%-2.33%-2.54%53.86%143.59%-28.34%-0.36%-12.76%-21.36%14.79%52.27%17.85%
Operating Expenses1.65B1.37B357.98M303.82M296.95M300.51M302.88M286.34M261.67M248.64M239.28M254.01M252.02M220.74M208.82M221.26M262.16M6.73M179.79M167.4M185.74M157.42M115.51M94.35M78.97M70.06M67.03M55.63M49.78M38.55M26.5M
OpEx / Revenue %26.89%22.79%6.54%6.56%8.15%7.53%8%7.21%7.74%7.28%7.41%8.44%8.37%7.82%7.5%7.97%9.44%0.22%7.45%5.27%5.86%5.26%4.33%4.16%4.42%4.65%4.91%4.34%4.07%3.42%3.21%
Depreciation & Amortization77.59M74.99M73.43M72.24M82.39M79.06M68.46M64.73M58.79M55.34M53.26M47.84M28.05M30.59M36.97M40.66M40.73M35.69M27.04M26.32M24.26M18.78M16.19M16.13M10.23M8.48M6.93M6.9M5.44M5.16M4.07M
Combined Ratio %83.03%88.93%89.5%97.85%118.41%92.5%87.88%90.48%100.91%95.11%97.81%97.66%91.78%95.32%95.14%91.17%93.43%81.69%118.68%90.09%90.14%88.21%84.71%89.15%96.6%91.72%90.59%86.84%80.75%81.4%83.44%
Operating Income1.04B663.65M574.88M99.43M-670.72M299.31M458.5M378.07M-30.61M167.09M70.72M70.57M247.43M132.1M135.31M245.1M182.39M571.54M-450.86M315.04M312.41M352.64M407.84M245.8M60.67M124.81M128.56M168.54M235.28M209.78M136.59M
Operating Margin %16.97%11.07%10.5%2.15%-18.41%7.5%12.12%9.52%-0.91%4.89%2.19%2.34%8.22%4.68%4.86%8.83%6.57%18.31%-18.68%9.91%9.86%11.79%15.29%10.85%3.4%8.28%9.41%13.16%19.25%18.6%16.56%
Operating Income Growth %-15.44%478.19%114.82%-324.09%-34.72%21.27%1334.91%-118.32%136.25%0.22%-71.48%87.31%-2.38%-44.79%34.38%-68.09%226.77%-243.11%0.84%-11.41%-13.54%65.92%305.16%-51.39%-2.91%-23.72%-28.37%12.16%53.58%19.48%
EBITDA1.12B738.64M648.31M171.67M-588.33M378.36M526.96M442.8M28.18M222.43M123.98M118.41M275.48M162.68M172.28M285.76M223.13M607.23M-423.82M341.36M336.67M371.42M424.04M261.93M70.9M133.29M135.48M175.44M240.72M214.94M140.66M
EBITDA Margin %18.23%12.33%11.84%3.71%-16.15%9.47%13.92%11.15%0.83%6.51%3.84%3.93%9.15%5.77%6.19%10.29%8.04%19.45%-17.56%10.74%10.62%12.41%15.89%11.56%3.97%8.84%9.92%13.7%19.7%19.06%17.05%
Interest Expense28.25M28.62M30.82M24.17M17.23M17.11M17.05M17.04M17.04M15.17M3.96M3.17M2.64M1.26M1.54M5.55M6.81M6.73M4.97M8.59M9.18M7.22M4.22M3.06M4.1M7.73M7.29M5M4.8M5M2M
Non-Operating Income-21.43M-28.62M-30.82M-24.17M-17.23M-17.11M-17.05M-17.04M-17.04M-15.17M-3.96M-3.17M-2.64M-1.26M-1.54M-5.55M-6.81M-6.73M-4.97M-8.59M-9.18M-7.22M-4.22M-3.06M-4.1M-7.73M-7.29M-5M-4.8M-5M-2M
Pretax Income1.04B663.65M574.88M99.43M-670.72M299.31M458.5M378.07M-30.61M167.09M70.72M70.57M247.43M132.1M135.31M245.1M182.39M571.54M-450.86M315.04M312.41M352.64M407.84M245.8M60.67M124.81M128.56M168.54M235.28M209.78M136.59M
Pretax Margin %16.97%11.07%10.5%2.15%-18.41%7.5%12.12%9.52%-0.91%4.89%2.19%2.34%8.22%4.68%4.86%8.83%6.57%18.31%-18.68%9.91%9.86%11.79%15.29%10.85%3.4%8.28%9.41%13.16%19.25%18.6%16.56%
Income Tax201.75M122.56M106.93M3.09M-158.04M51.37M83.89M57.98M-24.89M22.21M-2.32M-3.91M69.48M19.95M18.4M53.94M30.19M168.47M-208.74M77.2M97.59M99.38M121.64M61.48M-5.44M19.47M19.19M34.83M57.75M53.47M30.83M
Effective Tax Rate %19.37%18.47%18.6%3.11%23.56%17.16%18.3%15.34%81.29%13.29%-3.28%-5.54%28.08%15.1%13.6%22.01%16.55%29.48%46.3%24.51%31.24%28.18%29.82%25.01%-8.96%15.6%14.93%20.67%24.55%25.49%22.57%
Net Income839.84M541.09M467.95M96.34M-512.67M247.94M374.61M320.09M-5.73M144.88M73.04M74.48M177.95M112.14M116.91M191.16M152.2M403.07M-242.12M237.83M214.82M253.26M286.21M184.32M66.11M105.34M109.37M133.71M177.53M156.31M105.76M
Net Margin %13.68%9.03%8.55%2.08%-14.07%6.21%9.9%8.06%-0.17%4.24%2.26%2.47%5.91%3.98%4.2%6.88%5.48%12.91%-10.03%7.48%6.78%8.46%10.73%8.14%3.7%6.99%8.01%10.44%14.53%13.86%12.82%
Net Income Growth %193.48%15.63%385.75%118.79%-306.78%-33.81%17.03%5688.11%-103.95%98.34%-1.93%-58.15%58.68%-4.08%-38.84%25.6%-62.24%266.48%-201.8%10.71%-15.18%-11.51%55.28%178.83%-37.25%-3.68%-18.21%-24.68%13.58%47.79%17.12%
EPS (Diluted)15.169.778.451.74-9.264.486.775.78-0.102.621.321.353.232.042.133.492.787.32-4.414.343.924.635.243.381.211.942.022.443.212.821.93
EPS Growth %193.99%15.62%385.63%118.79%-306.7%-33.83%17.13%5880%-103.82%98.48%-2.22%-58.2%58.33%-4.23%-38.97%25.54%-62.02%265.99%-201.61%10.71%-15.33%-11.64%55.03%179.34%-37.63%-3.96%-17.21%-23.99%13.83%46.11%16.27%
EPS (Basic)-9.778.451.74-9.264.486.775.78-0.102.621.321.353.232.042.133.492.787.36-4.424.353.934.645.253.391.221.942.022.453.232.841.93
Diluted Shares Outstanding55.39M55.39M55.38M55.37M55.37M55.37M55.36M55.36M55.34M55.33M55.3M55.21M55.02M54.96M54.92M54.84M54.83M55.09M54.92M54.83M54.8M54.7M54.62M54.53M54.63M54.3M54.14M54.8M55.3M55.43M54.96M

Key Metrics

Growth RegimeStable
ProfitabilityModerate
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

California Regulatory Rate Lag

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Premium Growth Reflects Rate Adjustments

As reported in financial statements, Mercury General's top-line growth of 10.5% in 2026Q1 appears driven by necessary rate increases rather than volume expansion, suggesting that the company is successfully navigating the challenging California pricing environment to offset persistent inflationary pressures on its core personal auto segment.

The consistent revenue growth suggests that the company maintains pricing power despite the regulatory hurdles inherent in the California market. Investors should monitor whether this growth trajectory can be sustained through policy count expansion or if it remains strictly a function of premium rate adjustments.

Underwriting Profitability Shows Cyclical Recovery

Based on the provided quarterly data, the combined ratio improved to 84.7% in 2026Q1 from a peak of 110.2% in 2025Q1, indicating that the company has successfully returned to underwriting profitability after a period of significant margin compression caused by elevated claims severity and delayed rate approvals.

The volatility in the combined ratio highlights the company's sensitivity to external cost factors, particularly medical and repair inflation. The recent improvement suggests that the regulatory backlog is clearing, allowing premiums to better align with the underlying loss costs.

2025Q1 Loss Ratio Represents Inflection

According to the historical income statement data, the 2025Q1 period marked a critical inflection point where the loss ratio spiked to 104.0%, forcing a strategic pivot in pricing and underwriting discipline that has since facilitated a recovery in operating income across subsequent reporting quarters.

This period serves as a stark reminder of the risks associated with geographic concentration in a highly regulated state. The subsequent stabilization suggests that management has effectively recalibrated its risk appetite to restore profitability in the face of adverse loss trends.

Regulatory Concentration Risks Remain Elevated

While recent margins appear robust, the company's extreme reliance on the California market, as noted in historical filings, warrants caution, as any future legislative shifts or prolonged delays in the rate-filing cycle could rapidly erode the underwriting gains achieved over the last several quarters.

The lack of geographic diversification leaves the company uniquely vulnerable to state-specific catastrophe events and regulatory changes. Investors should consider whether the current valuation adequately prices in the potential for future regulatory friction that could disrupt the current margin expansion trend.

MCY — Frequently Asked Questions

Quick answers to the most common questions about buying MCY stock.

What was Mercury General Corporation's (MCY) revenue in 2025?

For fiscal year 2025, Mercury General Corporation (MCY) reported total revenue of $5.99B. This represents a 626.4% increase compared to $825.0M in 1996.

Is Mercury General Corporation (MCY) profitable?

Mercury General Corporation (MCY) is profitable, generating $541.1M in net income for the fiscal year ending 2025 with a net profit margin of 9.0%.

What is Mercury General Corporation's operating profit margin?

Mercury General Corporation (MCY) reported an operating income of $663.6M, resulting in an operating profit margin of 11.1%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Mercury General Corporation's gross profit and gross margin?

Mercury General Corporation (MCY) generated $2.03B in gross profit for the year, representing a gross profit margin of 33.9%. This demonstrates the company's core pricing power and production efficiency.